John C. Pottage's most recent trade in Spero Therapeutics Inc was a trade of 20,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 23, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Spero Therapeutics Inc | John C. Pottage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2026 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Spero Therapeutics Inc | John C. Pottage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2026 | 10,000 | 85,000 (0%) | 0% | 0 | Common Stock | |
| Spero Therapeutics Inc | John C. Pottage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 20,000 | 75,000 (0%) | 0% | 0 | Common Stock | |
| Spero Therapeutics Inc | John C. Pottage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 20,000 | 55,000 (0%) | 0% | 0 | Common Stock | |
| Spero Therapeutics Inc | John C. Pottage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2022 | 15,000 | 15,000 (0%) | 0% | 0 | Common Stock | |
| Spero Therapeutics Inc | John C. Pottage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 7,500 | 7,500 | - | - | Stock Option (right to buy) |